TEVA vs. WAT: Teva Pharmaceutical vs. Waters Stock Comparison

November 11, 2026

How do Teva Pharmaceutical (TEVA) and Waters (WAT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Teva Pharmaceutical (TEVA) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but TEVA is classified in Pharmaceuticals while WAT is classified in Life Sciences Tools & Services.

Waters (WAT) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Teva Pharmaceutical (TEVA) and Waters (WAT)
Profile Item	TEVA	WAT
Name	Teva Pharmaceutical Industries Ltd. ADR	Waters Corporation
Country/Region	Israel	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	49.72 billion USD	44.93 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	February 16, 1982	November 17, 1995
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

TEVA

WAT

GSPC

Teva Pharmaceutical (TEVA) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Teva Pharmaceutical (TEVA) and Waters (WAT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Teva Pharmaceutical (TEVA) and Waters (WAT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
Total Return (1Y)	79.58%	27.70%
Total Return (3Y, Annualized)	69.94%	23.32%
Total Return (5Y, Annualized)	35.86%	6.27%

Risk Profile

Drawdown History

TEVA

WAT

GSPC

Teva Pharmaceutical (TEVA) vs. Waters (WAT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Teva Pharmaceutical (TEVA) and Waters (WAT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
Volatility (1Y, Annualized)	33.95%	35.45%
Beta (5Y)	0.96	1.13
Max Drawdown (5Y)	-43.70%	-36.47%
Avg. Volume (3M)	5.91M	816.72K

Risk-Adjusted Performance

Risk-Return Positioning

TEVA and WAT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
Sharpe Ratio (1Y)	2.22	0.66
Sortino Ratio (1Y)	3.94	0.98

Profitability

ROE (TTM)

Teva Pharmaceutical (TEVA) at 6.65% sits in the top ROE quartile, while Waters (WAT) at 1.12% is closer to the peer norm — stronger capital efficiency for TEVA.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.65%

Max: 109.18%
TEVA: 6.65%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12%

Max: 109.18%
Q3: 6.23%
WAT: 1.12%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Teva Pharmaceutical (TEVA) at 2.94% and Waters (WAT) at 1.76% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.94%

Max: 18.05%
Q3: 4.78%
TEVA: 2.94%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.76%

Max: 18.05%
Q3: 4.78%
WAT: 1.76%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Teva Pharmaceutical (TEVA) at 27.40% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.40%

Max: 83.12%
TEVA: 27.40%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.38%

Max: 83.12%
Q3: 14.77%
WAT: 11.38%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
ROE (TTM)	6.65%	1.12%
ROA (TTM)	5.35%	2.36%
Net Margin (TTM)	2.94%	1.76%
Operating Margin (TTM)	27.40%	11.38%
Gross Margin (TTM)	53.51%	49.83%

Growth

Revenue Growth

Both Teva Pharmaceutical (TEVA) at 4.31% and Waters (WAT) at 6.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Waters (WAT) reports EPS growth of 0.47%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
Revenue Growth (YoY)	4.31%	6.99%
Revenue Growth (3Y CAGR)	4.96%	2.12%
EPS Growth (YoY)	--	0.47%
EPS Growth (3Y CAGR)	--	-2.84%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Teva Pharmaceutical (TEVA) shows current ratio of 0.95 against its industry benchmark, while Waters (WAT) has no reading this period.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.95

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TEVA: 0.95
Min: 0.10

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10
WAT: --

Teva Pharmaceutical (TEVA) vs. Waters (WAT): WAT does not report current ratio, so it has no value marker; TEVA is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

Waters (WAT) at 0.34 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.13

TEVA: 2.13
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.34

Max: 1.42
Q3: 0.65
WAT: 0.34
Median: 0.15
Q1: 0.02
Min: 0.00

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
Current Ratio (MRQ)	0.95	--
Debt / Equity (MRQ)	2.13	0.34
Net Debt / EBITDA	2.93	3.23

Dividends

Dividend Yield (TTM)

Neither Teva Pharmaceutical (TEVA) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEVA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Teva Pharmaceutical (TEVA) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEVA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

WAT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Both Teva Pharmaceutical (TEVA) at 99.09 and Waters (WAT) at 191.46 trade above their industries’ P/E ratio peer ranges, pointing to unusually expensive trailing earnings relative to peers.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

99.09

TEVA: 99.09
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

191.46

WAT: 191.46
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Waters (WAT) at 8.01 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.89

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
TEVA: 2.89
Min: 0.01

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.01

Max: 58.18
Q3: 25.77
WAT: 8.01
Median: 7.30
Q1: 3.01
Min: 0.01

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Teva Pharmaceutical (TEVA) at 6.23 and Waters (WAT) at 2.94 are valued close to their industries’ norm against book — neither stands out from peers.

TEVA

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.23

Max: 13.53
Q3: 6.54
TEVA: 6.23
Median: 3.25
Q1: 1.69
Min: -5.59

WAT

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.94

Max: 13.53
Q3: 6.54
Median: 3.25
WAT: 2.94
Q1: 1.69
Min: -5.59

Teva Pharmaceutical (TEVA) vs. Waters (WAT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Teva Pharmaceutical (TEVA) and Waters (WAT)
Metric	TEVA	WAT
P/E Ratio (TTM)	99.09	191.46
P/S Ratio (TTM)	2.89	8.01
P/B Ratio (MRQ)	6.23	2.94
Free Cash Flow Yield (TTM)	3.00%	--